倍他乐克治疗慢性充血性心力衰竭的临床观察  

Observe the Efficiency of β-blocker in Chronic Heartfailure Diease

作　　者：张莉[1] 夏立志[1] 

机构地区：[1]哈尔滨二四二医院心内科,黑龙江哈尔滨150060

出　　处：《黑龙江医学》2006年第8期592-593,共2页Heilongjiang Medical Journal

摘　　要：目的观察倍他乐克治疗慢性充血性心力衰竭的疗效及安全性。方法选择100例慢性充血性心力衰竭患者,随机单盲分成倍他乐克治疗组(治疗组)与常规治疗组(对照组)各50例。结果治疗组均可耐受合适剂量的倍他乐克。6个月后治疗组及对照组左室射血分数均有所增加,但治疗组显著高于对照组(P<0.05);与对照组相比,6个月后治疗组左室收缩末期容积及舒张末期容积均显著缩小。治疗前后两组心功能分级均明显改善,但治疗组明显优于对照组(P<0.05)。结论倍他乐克治疗慢性心力衰竭是安全、有效的。Objective To investigate the efficacy and safety of β- blockerin chronic heart diease. Methods One hundred chronic heartfailure patients were divided randomly into observational group and control group for a follow - up period of six months. Each group has fifty patients. Results At the end of the study, LV ejection fraction（LVEF） increased in both groups, with the range of LVEF increasing more significantly in β- blocker group （ P 〈 0.05） ; the left ventricular end - systolic volume index and the left ventricuar and - diastolic volume index were decreased obviously in β- blocker group compared with those in control group after six months. The grade of heart funfion were improved in both groups,with the rangeof increasing more significantly in β- blocker group（ P 〈 0.05） .Conclusion β- blocker is a quite safe and efficient agent in chronic hearffailure diease.

关 键 词：倍他乐克 充血性心力衰竭 

分 类 号：R541.6[医药卫生—心血管疾病]